Does the media refer more to PAHC or AMRX?

In the previous week, Phibro Animal Health had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Phibro Animal Health and 6 mentions for Amneal Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.77 beat Amneal Pharmaceuticals' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MANE or PAHC?

In the previous week, Phibro Animal Health had 16 more articles in the media than Veradermics. MarketBeat recorded 19 mentions for Phibro Animal Health and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.94 beat Phibro Animal Health's score of 0.77 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PAHC or INDV?

In the previous week, Phibro Animal Health had 12 more articles in the media than Indivior. MarketBeat recorded 19 mentions for Phibro Animal Health and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Phibro Animal Health's score of 0.77 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor OGN or PAHC?

In the previous week, Phibro Animal Health had 13 more articles in the media than Organon & Co.. MarketBeat recorded 19 mentions for Phibro Animal Health and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.82 beat Phibro Animal Health's score of 0.77 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PAHC or GPCR?

In the previous week, Phibro Animal Health had 15 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Phibro Animal Health and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Phibro Animal Health's score of 0.77 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Phibro Animal Health (PAHC) Competitors

$37.67 +1.32 (+3.63%)

As of 08/28/2026 04:00 PM Eastern

Compare

PAHC vs. AMRX, MANE, INDV, OGN, and GPCR

Should you buy Phibro Animal Health stock or one of its competitors? Phibro Animal Health's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Veradermics (MANE), Indivior (INDV), Organon & Co. (OGN), and Structure Therapeutics (GPCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Phibro Animal Health (NASDAQ:PAHC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phibro Animal Health presently has a consensus target price of $47.67, suggesting a potential upside of 26.54%. Amneal Pharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 8.32%. Given Phibro Animal Health's higher probable upside, equities research analysts clearly believe Phibro Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80

In the previous week, Phibro Animal Health had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Phibro Animal Health and 6 mentions for Amneal Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.77 beat Amneal Pharmaceuticals' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a net margin of 6.57% compared to Amneal Pharmaceuticals' net margin of 5.05%. Phibro Animal Health's return on equity of 37.86% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Summary

Phibro Animal Health beats Amneal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Phibro Animal Health compare to Veradermics?

Veradermics (NYSE:MANE) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Phibro Animal Health has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 56.70%. Phibro Animal Health has a consensus price target of $47.67, suggesting a potential upside of 26.54%. Given Veradermics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Veradermics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Phibro Animal Health had 16 more articles in the media than Veradermics. MarketBeat recorded 19 mentions for Phibro Animal Health and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.94 beat Phibro Animal Health's score of 0.77 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a net margin of 6.57% compared to Veradermics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Phibro Animal Health	6.57%	37.86%	9.18%

99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Phibro Animal Health beats Veradermics on 10 of the 14 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Phibro Animal Health currently has a consensus target price of $47.67, indicating a potential upside of 26.54%. Indivior has a consensus target price of $45.17, indicating a potential upside of 29.53%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, Phibro Animal Health had 12 more articles in the media than Indivior. MarketBeat recorded 19 mentions for Phibro Animal Health and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Phibro Animal Health's score of 0.77 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Indivior has lower revenue, but higher earnings than Phibro Animal Health. Indivior is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44
Indivior	$1.24B	3.32	$210M	$2.79	12.50

Indivior has a net margin of 26.65% compared to Phibro Animal Health's net margin of 6.57%. Phibro Animal Health's return on equity of 37.86% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Indivior	26.65%	-283.11%	36.85%

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Indivior beats Phibro Animal Health on 10 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 17.21%. Phibro Animal Health has a consensus price target of $47.67, indicating a potential upside of 26.54%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Phibro Animal Health had 13 more articles in the media than Organon & Co.. MarketBeat recorded 19 mentions for Phibro Animal Health and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.82 beat Phibro Animal Health's score of 0.77 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.88
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44

Phibro Animal Health has a net margin of 6.57% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Phibro Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Phibro Animal Health	6.57%	37.86%	9.18%

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Phibro Animal Health pays an annual dividend of $0.48 per share and has a dividend yield of 1.3%. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Phibro Animal Health pays out 19.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Summary

Phibro Animal Health beats Organon & Co. on 11 of the 18 factors compared between the two stocks.

How does Phibro Animal Health compare to Structure Therapeutics?

Phibro Animal Health (NASDAQ:PAHC) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its stock price is 243% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

In the previous week, Phibro Animal Health had 15 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Phibro Animal Health and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Phibro Animal Health's score of 0.77 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health presently has a consensus target price of $47.67, suggesting a potential upside of 26.54%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.57% compared to Structure Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Structure Therapeutics	N/A	-25.56%	-24.31%

Summary

Phibro Animal Health beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.53B	$12.15B	$7.20B	$12.91B
Dividend Yield	1.27%	2.62%	2.54%	11.28%
P/E Ratio	15.44	787.65	273.16	25.45
Price / Sales	1.01	795.08	634.73	93.93
Price / Cash	8.24	91.95	76.74	53.00
Price / Book	3.97	11.97	12.98	6.14
Net Income	$48.26M	$2.83B	$3.48B	$348.86M
7 Day Performance	3.72%	0.39%	0.13%	-0.80%
1 Month Performance	3.35%	5.34%	7.08%	4.13%
1 Year Performance	1.62%	6.05%	24.67%	15.17%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.1705 of 5 stars	$37.67 +3.6%	$47.67 +26.5%	+1.6%	$1.53B	$1.52B	15.44	2,475	News Coverage Earnings Report
AMRX Amneal Pharmaceuticals	3.4762 of 5 stars	$17.92 +0.8%	$17.67 -1.4%	+83.5%	$5.72B	$3.02B	36.57	8,500	Analyst Forecast
MANE Veradermics	2.6695 of 5 stars	$102.44 +4.0%	$153.00 +49.4%	N/A	$4.28B	N/A	N/A	19	News Coverage
INDV Indivior	4.4053 of 5 stars	$35.97 -0.6%	$45.17 +25.6%	+43.6%	$4.24B	$1.33B	12.89	1,051	News Coverage Positive News
OGN Organon & Co.	1.8387 of 5 stars	$13.76 +0.0%	$11.40 -17.1%	+46.6%	$3.61B	$6.22B	17.86	10,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, MANE, INDV, OGN, and GPCR

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Summary

How does Phibro Animal Health compare to Veradermics?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Summary

How does Phibro Animal Health compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, MANE, INDV, OGN, and GPCR

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Do insiders and institutionals believe in PAHC or AMRX?

Do analysts rate PAHC or AMRX?

Which has more risk and volatility, PAHC or AMRX?

Which has stronger valuation and earnings, PAHC or AMRX?

Does the media refer more to PAHC or AMRX?

Is PAHC or AMRX more profitable?

Summary

How does Phibro Animal Health compare to Veradermics?

Which has stronger earnings and valuation, MANE or PAHC?

Do analysts prefer MANE or PAHC?

Does the media favor MANE or PAHC?

Is MANE or PAHC more profitable?

Do insiders & institutionals hold more shares of MANE or PAHC?

Summary

How does Phibro Animal Health compare to Indivior?

Do analysts rate PAHC or INDV?

Which has more risk & volatility, PAHC or INDV?

Does the media refer more to PAHC or INDV?

Which has higher valuation & earnings, PAHC or INDV?

Is PAHC or INDV more profitable?

Do insiders and institutionals believe in PAHC or INDV?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Do analysts prefer OGN or PAHC?

Does the media favor OGN or PAHC?

Which has preferable earnings & valuation, OGN or PAHC?

Is OGN or PAHC more profitable?

Is OGN or PAHC a better dividend stock?

Do institutionals and insiders hold more shares of OGN or PAHC?

Which has more risk & volatility, OGN or PAHC?

Summary

How does Phibro Animal Health compare to Structure Therapeutics?

Which has more volatility & risk, PAHC or GPCR?

Which has preferable valuation & earnings, PAHC or GPCR?

Does the media refer more to PAHC or GPCR?

Do analysts prefer PAHC or GPCR?

Do institutionals and insiders believe in PAHC or GPCR?

Is PAHC or GPCR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools